🦠

Infectious Disease

109 drugs in pipeline from 10 companies

109

Drugs in Pipeline

Companies

Upcoming Catalysts

109

Phase 3 Trials

Upcoming Catalysts

SNYPhase 2$115.3B

RSV/hMPV vaccine candidate Dose L Phase 2 Results Expected

RSV/hMPV vaccine candidate Dose L• Respiratory Syncytial Virus Infection646

Mar 10Estimated

CT.gov

00%

UEECAdCom$18M

Advisory Committee - Influenza virus vaccine

Mar 12AI-detected

Source

00%

BNTXPhase 2$26.6B

BNT164a1 Phase 2 Results Expected

BNT164a1• Tuberculosis497

Mar 15Estimated

CT.gov

00%

VIRPhase 2$746M

VIR-2218 Phase 2 Results Expected

VIR-2218• Hepatitis B, Chronic244

Mar 15Estimated

CT.gov

00%

SVAPhase 3$642M

Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV Phase 3 Results Expected

Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV• Influenza150

Mar 15Estimated

CT.gov

00%

VIRPhase 2$746M

VIR-3434 Phase 2 Results Expected

VIR-3434• Hepatitis B, Chronic244

Mar 15Estimated

CT.gov

00%

View all catalysts

Pipeline by Phase

Phase 3

109

Active Companies

GILD

Gilead Sciences, Inc.

GSK plc

Novartis AG

NOVARTIS AG

MERCK

BRISTOL MYERS SQUIBB CO

Roche Holding AG

Sanofi

Sanofi

ABBOTT LABORATORIES

Related Conditions

infectiousviralbacterialfungalhivaidshepatitiscovidcoronavirusrsvinfluenzafluantibioticantiviralvaccinesepsistuberculosismalariaherpescmvebv